Rituximab for Pemphigus Vulgaris
Authors:
- Pascal JolyPJPascal Joly
- Michel D'IncanMDMichel D'Incan
- Philippe MusettePMPhilippe Musette
- 1 February 2007
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 356 (5) , 521-522
Abstract
Ahmed et al. (Oct. 26 issue)1 report a resolution of pemphigus in 9 of 11 patients with refractory disease treated with a combination of 10 infusions of rituximab and 6 of intravenous immune globulin. On the basis of our experience with more than 20 patients with severe pemphigus who were treated with only one cycle of four infusions of rituximab,2 we confirm that rituximab has a dramatic effect: more than 90% of our patients had a complete remission, which was maintained after a 24-month follow-up period in two thirds of the patients. We did not treat the patients with intravenous immune globulin, and we observed only two cases of late infections. A single cycle of rituximab should be compared with the combination regimen proposed by Ahmed et al. in a clinical trial.Keywords
This publication has 3 references indexed in Scilit:
- Treatment of Pemphigus Vulgaris with Rituximab and Intravenous Immune GlobulinNew England Journal of Medicine, 2006
- Rituximab: A monoclonal antibody to CD20 used in the treatment of pemphigus vulgarisJournal of the American Academy of Dermatology, 2006
- Free Communications – Part IJournal of Investigative Dermatology, 2006